Lead story
Foghorn Therapeutics Stock Extends Decline After Eli Lilly Partnership Ends
Shares of Foghorn Therapeutics plunged for a second day after the company and partner Eli Lilly terminated their collaboration, halting development of a key drug candidate and prompting a wave of analyst downgrades.















